Shopping Cart 0
Cart Subtotal
USD 0

Rexahn Pharmaceuticals Inc (RNN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Rexahn Pharmaceuticals Inc (Rexahn Pharmaceuticals), formerly Corporate Road Show.com Inc is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of cancer. The company develops anti-cancer drug candidates including Archexin that is intended for the treatment of pancreatic cancer. It develops RX-3117 used for the treatment of pancreatic, bladder, colon, and lung cancer. The company also offers Supinoxin for solid tumors. It provides pre-clinical development of products intended for the treatment of tumors. The company partners with other pharmaceutical companies for oncology product development. Rexahn Pharmaceuticals is headquartered in Rockville, Maryland, the US.

Rexahn Pharmaceuticals Inc (RNN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Rexahn Pharma Enters into Clinical Trial Collaboration Agreement with Merck 11

Licensing Agreements 12

Zhejiang Haichang Biotechnology Enters into Licensing Agreement with Rexahn Pharma 12

Rexahn Pharma Enters Into Licensing Agreement With University of Maryland For Nano-Polymer-Drug Conjugate Systems 13

Rexahn Pharma Enters Into Licensing Agreement With Ohio State Innovation Foundation For Oligonucleotide Drug Delivery Platform 14

Equity Offering 15

Rexahn Pharma Raises USD8 Million in Private Placement of Units 15

Rexahn Pharma Raises USD10 Million in Private Placement of Shares and Warrants 17

Rexahn Pharma Raises USD6 Million in Private Placement of Shares and Warrants 18

Rexahn Pharma Raises USD5 Million in Private Placement of Units 19

Rexahn Pharma to Raise up to USD7 Million in Private Placement of Units 21

Rexahn Pharma Completes Private Placement Of Units For USD 20 Million 22

Rexahn Pharma Completes Private Placement Of Units For USD 5.3 Million 23

Rexahn Pharma Completes Public Offering Of Units For USD 5.7 Million 24

Rexahn Pharma Completes Public Offering Of Common Stock For USD 6.6 Million 25

Acquisition 27

Pfizer Rumored To Acquire Rexahn Pharma 27

Rexahn Pharmaceuticals Inc-Key Competitors 28

Rexahn Pharmaceuticals Inc-Key Employees 29

Rexahn Pharmaceuticals Inc-Locations And Subsidiaries 30

Head Office 30

Recent Developments 31

Financial Announcements 31

Aug 06, 2018: Rexahn Reports Second Quarter 2018 Financial Results 31

May 07, 2018: Rexahn Announces First Quarter 2018 Financial Results 33

Mar 12, 2018: Rexahn Pharmaceuticals Announces Full Year 2017 Financial Results 34

Nov 06, 2017: Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 36

Aug 07, 2017: Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results 38

May 04, 2017: Rexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 40

Feb 27, 2017: Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update 42

Corporate Communications 44

Jan 04, 2018: Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer 44

Sep 01, 2017: Rexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors 45

Clinical Trials 46

Jun 04, 2017: Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology 2017 Annual Meeting 46

May 08, 2017: Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting 48

Jan 20, 2017: Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium 49

Other Significant Developments 51

Aug 07, 2018: Rexahn Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans 51

Aug 14, 2017: Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Rexahn Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Rexahn Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Rexahn Pharma Enters into Clinical Trial Collaboration Agreement with Merck 11

Zhejiang Haichang Biotechnology Enters into Licensing Agreement with Rexahn Pharma 12

Rexahn Pharma Enters Into Licensing Agreement With University of Maryland For Nano-Polymer-Drug Conjugate Systems 13

Rexahn Pharma Enters Into Licensing Agreement With Ohio State Innovation Foundation For Oligonucleotide Drug Delivery Platform 14

Rexahn Pharma Raises USD8 Million in Private Placement of Units 15

Rexahn Pharma Raises USD10 Million in Private Placement of Shares and Warrants 17

Rexahn Pharma Raises USD6 Million in Private Placement of Shares and Warrants 18

Rexahn Pharma Raises USD5 Million in Private Placement of Units 19

Rexahn Pharma to Raise up to USD7 Million in Private Placement of Units 21

Rexahn Pharma Completes Private Placement Of Units For USD 20 Million 22

Rexahn Pharma Completes Private Placement Of Units For USD 5.3 Million 23

Rexahn Pharma Completes Public Offering Of Units For USD 5.7 Million 24

Rexahn Pharma Completes Public Offering Of Common Stock For USD 6.6 Million 25

Pfizer Rumored To Acquire Rexahn Pharma 27

Rexahn Pharmaceuticals Inc, Key Competitors 28

Rexahn Pharmaceuticals Inc, Key Employees 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Rexahn Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.